Clinical trials of a single vaccine against influenza and coronavirus will begin at the end of 2022, Director of the Gamaleya Center Alexander Gintsburg told “Izvestia” newspaper, Day.Az reports with reference to Gazeta.ru. The technological platform of the future drug will consist of a hybrid vaccine against rotavirus and various variants of the coronavirus, the Russian scientist said.
"If the new platform recommends itself well, we plan to switch to the option of combining influenza hemagglutinin antigens and, accordingly, coronavirus S-proteins in one vaccine," he said.
The hybrid vaccine is designed to reduce mortality while being infected with these diseases.
